Caxton Associates LP Adverum Biotechnologies, Inc. Transaction History

Caxton Associates LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.81 - $1.34 $263,685 - $436,220	-325,538 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.74 - $2.4 $349,197 - $481,651	200,688 Added 160.74%	325,538 $573,000
Q3 2021 Nov 15, 2021	BUY	$2.08 - $3.6 $200,986 - $347,860	96,628 Added 342.39%	124,850 $271,000
Q2 2021 Aug 16, 2021	BUY	$3.36 - $10.56 $94,825 - $298,024	28,222 New	28,222 $99,000
Q2 2020 Aug 14, 2020	SELL	$8.53 - $25.64 $226,642 - $681,254	-26,570 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$7.98 - $16.32 $212,028 - $433,622	26,570 New	26,570 $260,000

2.53M

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $689M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.